NL-OMON26724
Completed
Not Applicable
Effect of 2 versus 3 pneumococcal conjugate vaccinations Prevnar on nasopharyngeal carriage, transmission and herd immunity;a randomized, controlled study
Prof Dr EAM SandersUniversity Medical Center UtrechtDepartment of Pediatric ImmunologyHP 06.063.0Lundlaan 6POBox 850903508 AB Utrecht, The NetherlandsPhone 31 30 2504000Fax 31 30 2505350email l.sanders@umcutrecht.nl0 sites1,000 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prevention of invasive pneumococcal disease in healthy infants
- Sponsor
- Prof Dr EAM SandersUniversity Medical Center UtrechtDepartment of Pediatric ImmunologyHP 06.063.0Lundlaan 6POBox 850903508 AB Utrecht, The NetherlandsPhone 31 30 2504000Fax 31 30 2505350email l.sanders@umcutrecht.nl
- Enrollment
- 1000
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1000 healthy newborns (and family members) who will receive childhood vaccinations according to the national vaccination program, starting at 2 months of age.
Exclusion Criteria
- •Exclusion from the national vaccination program because of the presence of a medical condition requiring treatment that can interfere with the results of vaccinations,
- •known of suspected allergy to components of the vaccine,
- •known or suspected immunodeficiency disease other than IgA or IgG\-subclass deficiency,
- •previous treatment with plasma or immunoglobulins,
- •previous vaccinations other than hepatitis B vaccinations,
- •coagulations disorders.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effect of 2 versus 3 pneumococcal conjugate vaccinations Prevnar on nasopharyngeal carriage, transmission and herd immunity; a randomized, controlled study.Invasive pneumococcal disease, Respiratory tract infection. Added as of 22/05/2007: Change in: nasopharyngeal carriage after reduced doses 7-valent conjugate vaccine, antipneumococcal antibody development, family transmission of pneumococciInfections and InfestationsInvasive pneumococcal diseaseISRCTN25571720niversity Medical Centre Utrecht (UMCU) (Netherlands)1,003
Completed
Not Applicable
Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemiaISRCTN21541376Central Manchester and Manchester Children's Hospital (UK)97
Active, not recruiting
Phase 1
Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia - Pneumococcal conjugate vaccination in Haematology patients: Version 1Pneumococcal disease is a common form of meningitis, septicaemia and pneumonia. Those individuals at highest risk include children, the elderly and persons whose immune systems are impaired. This latter group is diverse includes patients with the haematological disorders myeloma and chronic lymphocytic leukaemia in whom infections are a leading cause of death.EUCTR2005-003761-16-GBDepartment of R & D, Central Manchester and Manchester Children's Hospital NHS Trust97
Completed
Phase 3
Effect of Two Versus Three Pneumococcal Conjugate VaccinationsStreptococcus Pneumoniae InfectionNCT00189020UMC Utrecht1,005
Not yet recruiting
Not Applicable
Efficacy of pneumococcal conjugate vaccine in preventing acquisition and carriage of pneumococcal vaccine serotypes in Tanzanian children with human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS)Pneumococcal diseaseHIV/AIDSPublic Health - EpidemiologyInfection - Studies of infection and infectious agentsACTRN12610000999033Prof Robert Booy216